Showing results (721-730 of 1,019) with videos related to

Sort By:
Pageof 102
Cancer Research|June 24, 2010
Genomic and biological characterization of exon 4 KRAS mutations in human cancerManickam Janakiraman, Efsevia Vakiani, Zhaoshi Zeng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2013
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancerMark A Socinski, Jonathan Goldman, Iman El-Hariry, et al.
Oncogene|November 13, 2001
Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing propertiesE Y Huang, M T Madireddi, R V Gopalkrishnan, et al.
Oncotarget|October 7, 2015
Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathwayRajmohan Murali, Raghu Chandramohan, Inga Möller, et al.
Science Translational Medicine|May 30, 2014
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemiaStephen S Chung, Eunhee Kim, Jae H Park, et al.
Blood|May 8, 2009
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesOmar Abdel-Wahab, Ann Mullally, Cyrus Hedvat, et al.
British Journal of Haematology|April 3, 2020
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre settingDiana Hanekamp, Alexander N Snel, Angèle Kelder, et al.
Frontiers in Oncology|October 27, 2022
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysisJesse M Tettero, Waleed K W Al-Badri, Lok Lam Ngai, et al.
Hemasphere|June 8, 2026
Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studiesCoen R Veenstra, Lok Lam Ngai, Patrycja Gradowska, et al.
European Urology|October 19, 2016
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell CarcinomaJames J Hsieh, David Chen, Patricia I Wang, et al.
Pageof 102